Human Genome Sciences said on Monday its experimental lupus drug Benlysta was successful in a late-stage clinical trial, paving the way for approval of the first treatment for the disease in 50 years.

Results of the trial, which were announced early on Monday, showed patients who took Benlysta experienced a statistically significant improvement in symptoms compared with those taking a placebo.

Lupus is a complex autoimmune disease that causes the immune system to attack the body's own tissue and organs, including the joints, kidneys, heart, lungs, brain, blood and skin. It can cause arthritis, kidney damage, chest pain and skin rash, among other disorders.
   
The trial, known as BLISS-76, is the second of two required by the US Food and Drug Administration in order for the drug to be considered for approval.

Human Genome and partner GlaxoSmithKline Plc have said they plan to file for approval in the first quarter of next year. The results follow similarly positive data from a trial known as BLISS-52 that were released in July. - Reuters